Biodexa Pharmaceuticals Plc (BDRX)
NASDAQ: BDRX · IEX Real-Time Price · USD
0.800
-0.140 (-14.94%)
At close: Jul 19, 2024, 4:00 PM
0.830
+0.029 (3.69%)
Pre-market: Jul 22, 2024, 7:39 AM EDT
Biodexa Pharmaceuticals Revenue
In the year 2023, Biodexa Pharmaceuticals had annual revenue of $482.28K.
Revenue (ttm)
$482.28K
Revenue Growth
-42.73%
P/S Ratio
0.39
Revenue / Employee
$22,966
Employees
21
Market Cap
189.21K USD
Revenue Chart
* The company reports in GBP currency but revenue data is shown in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 482.28K | -359.89K | -42.73% |
Dec 31, 2022 | 842.17K | 71.50K | 9.28% |
Dec 31, 2021 | 770.67K | 300.80K | 64.02% |
Dec 31, 2020 | 469.86K | -416.98K | -47.02% |
Dec 31, 2019 | 886.84K | -1.57M | -63.94% |
Dec 31, 2018 | 2.46M | 1.12M | 84.07% |
Dec 31, 2017 | 1.34M | -297.81K | -18.23% |
Dec 31, 2016 | 1.63M | -393.11K | -19.39% |
Dec 31, 2015 | 2.03M | 1.78M | 728.72% |
Dec 31, 2014 | 244.60K | 1.15K | 0.47% |
Dec 31, 2013 | 243.45K | - | - |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionBDRX News
- 2 days ago - Announces Pricing of $5.0 Million Registered Direct Offering and Concurrent Private Placement - GlobeNewsWire
- 10 days ago - Cancer-Focused Nano-Cap Biodexa Pharmaceuticals Stock Is Surging On Thursday - Here's Why - Benzinga
- 10 days ago - Biodexa Announces Additional Positive Results Of Phase 2 Trial Of eRapa in Treatment Of Precancerous Polyps in the GI Tract - Now 12-Month Data - Accesswire
- 19 days ago - Positive Phase 1 Clinical Data of MTX110 in DMG Brain Cancer Demonstrating Increased Survival Presented at ISPNO 2024 - GlobeNewsWire
- 27 days ago - Biodexa Announces Positive Phase 2 Clinical Trial Results of eRapa™ at 12 months in Familial Adenomatous Polyposis (FAP) - GlobeNewsWire
- 5 weeks ago - Results of Annual General Meeting - GlobeNewsWire
- 5 weeks ago - Twelve month Phase 2 Clinical Trial Results of eRapa™ in Familial Adenomatous Polyposis (FAP) to be Presented at Prestigious Biennial InSIGHT 2024 Meeting in Barcelona - GlobeNewsWire
- 7 weeks ago - Promising Phase 2 Results For Biodexa's eRapa(TM) Indicates Hope for FAP Patients Who Otherwise Have a 100% Lifetime Risk of Colorectal Cancer - Accesswire